Obtainment of anti-idiotypic (ID) monoclonal antibodies (mAb) capable to mimicry hFGF2

Abstract

Cancer corresponds to a set of diseases that have in common the disordered growth of cells, and have the capacity to invade neighboring and distant tissues and organs. Immunotherapy focused on the angiogenesis process may be an alternative to inhibit tumor growth. Based on this idea, our group successfully developed monoclonal antibodies (mAbs) that interfere with murine model tumor growth: mAb 3F12E7, an anti-hFGF2 (human fibroblast growth factor 2) antibody, and the anti-idiotype (Id) mAb from Bevacizumab , 10.D7, which mimics Vascular Endothelial Growth Factor (VEGF). Based on the idiotype network theory, the purpose of this project is to obtain anti-idiotypic monoclonal antibodies of mAb 3F12E7 that mimic hFGF2 to be used as immunogen. For that purpouse, BALB / c mice will be immunized with mAb 3F12E7 and then will have their splenocytes fused with myeloma cells, so to obtain the anti-Id monoclonal antibodies. The obtained Anti-Id mAb will be characterized on their ability to mimic hFGF2. (AU)